The Pacific Ovarian Cancer Research Consortium (POCRC) is a community-based, multidisciplinary, translational research program that involves clinicians, laboratory scientists and public health scientists from six research and medical institutions on the Pacific Coast. The community-based approach allows the pooling of clinical resources to facilitate population-based studies despite the low incidence of ovarian cancer. The themes of the program are biomarkers for risk and early detection of disease, molecular targets for prognosis and therapy, and antigens for immunotherapy. We hypothesize that through early detection we can improve outcomes significantly because currently available treatments are more effective in disease confined to the ovary; new, less toxic immunotherapeutic approaches are expected to be particularly effective in early-stage disease. The POCRC will conduct 5 translational research projects including a screening trial in high-risk women using serum markers validated in preclinical samples, a novel imaging trial using targeted microbubbles to improve ultrasound performance, validation of a microRNA plasma signature for respectability, exploration of restoration of wild-type BRCA1 function in the development of resistance to cicplatin, and a Phase 1 trial of an anti-lGFBP2 vaccine. Each project addresses at least one of the translational areas outlined in the SPORE guidelines and together the program addresses 5 of the 6 translational pathways defined by the TRWG, All projects build on work performed during the current and previous funding periods. A Developmental Research Program and a Career Development Program are also included as part of our Renewal. Projects are supported by a Leadership and Administration Core, a Clinical Specimen Management and Characterization Core, a Participant Recruitment, Enrollment and Characterization Core, and a Biostatistics and Data Management Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA083636-15S1
Application #
9132421
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Kuzmin, Igor A
Project Start
1999-09-30
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2016-06-30
Support Year
15
Fiscal Year
2015
Total Cost
$901,655
Indirect Cost
$309,731
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Kondrashova, Olga; Topp, Monique; Nesic, Ksenija et al. (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970
Hooda, Jagmohan; Novak, Marian; Salomon, Matthew P et al. (2018) Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res :
Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874
Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273
Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049
Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284
Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485
Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:
Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998

Showing the most recent 10 out of 187 publications